Pharmacogenomics

Related Pages on the Web

Personalised Medicines – hopes and realities (The Royal Society)

Each of the blockbusters released was also associated with rare but sometimes serious complications, and some complications that were not evident during clinical trials emerged with long term use. When a large number of people began taking these medications, even a tiny percentage of rare complications could become a significant number of affected patients. In some cases, these blockbusters have had to be removed from the market and/or their benefits versus their risks weighed carefully by the patients taking them and the doctors prescribing them.
N-acetyltransferase
Thiopurine methyltransferase (TPMT)
UDP-glucuronosyltransferase